Imutex Ltd. Collaboration.
In 2016 hVIVO formed a Joint Venture with the SEEK Group called Imutex Limited, with hVIVO owning 49%, to accelerate the development of a Broad-Spectrum ‘Universal’ Influenza Vaccine, FLU-v, and a Mosquito-Borne Diseases Vaccine, AGS-v.
The development of the FLU-v Universal Flu Vaccine and the AGS-v Mosquito-Borne Diseases vaccines are key public health priorities identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.
To find out more about the product developments, both in influenza vaccine development (FLU-v) and also mosquito-borne diseases vaccine development (AGS-v), please visit the Imutex website: www.imutex.com
To find out more about FLU-v click here.
To find out more about AGS-v click here.
If you are interested to find out more about these and other hVIVO developments and innovations, and how there may be a collaborative or partnering opportunity with your organisation, then please use the “Contact Us” form on this website.